Investigative Ophthalmology & Visual Science Cover Image for Volume 64, Issue 8
June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Topographic Analysis of Local Optical Coherence Tomography Biomarkers which Predict Progression to Atrophy in Age-related Macular Degeneration
Author Affiliations & Notes
  • Navid Manafi
    Doheny Eye Institute, Pasadena, California, United States
    Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Alireza Mahmoudi
    Doheny Eye Institute, Pasadena, California, United States
    Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Giulia Corradetti
    Doheny Eye Institute, Pasadena, California, United States
    Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Yu Wakatsuki
    Doheny Eye Institute, Pasadena, California, United States
    Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Stephanie Trejo Corona
    Retina Consultants of Texas, Houston, Texas, United States
  • Charles Clifton Wykoff
    Retina Consultants of Texas, Houston, Texas, United States
  • SriniVas R Sadda
    Doheny Eye Institute, Pasadena, California, United States
    Ophthalmology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Navid Manafi None; Alireza Mahmoudi None; Giulia Corradetti None; Yu Wakatsuki None; Stephanie Trejo Corona None; Charles Wykoff Apellis, Genentech, IVERIC Bio, Janssen, Novartis, Regeneron, Code C (Consultant/Contractor), Apellis, Genentech, IVERIC Bio, Janssen, Novartis, Regeneron, Code R (Recipient); SriniVas Sadda 4DMT, Abbvie/Allergan, Amgen, Apellis, Astellas, Bayer, Biogen, Boerhinger Ingelheim, Centervue, Genentech/Roche, Heidelberg Engineering, Iveric, Nanoscope, Novartis, Optos, Oxurion, Regeneron, Code C (Consultant/Contractor), Carl Zeiss Meditec, Code F (Financial Support), Nidek, Code R (Recipient), Centervue, Heidelberg Engineering, Nidek, Optos, Topcon, Code S (non-remunerative)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2141. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Navid Manafi, Alireza Mahmoudi, Giulia Corradetti, Yu Wakatsuki, Stephanie Trejo Corona, Charles Clifton Wykoff, SriniVas R Sadda; Topographic Analysis of Local Optical Coherence Tomography Biomarkers which Predict Progression to Atrophy in Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2141.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the association between presence of optical coherence tomography (OCT) biomarkers associated with a higher risk for progression to complete retinal pigment epithelium and outer retinal atrophy (cRORA) in age-related macular degeneration (AMD) in the same location as cRORA.

Methods : Patients with dry AMD who had evidence of cRORA and OCT data available for 48 ± 4 months prior to the first visit with evidence of cRORA were included in this retrospective case-control analysis. At the baseline visit, (48 months before the development of cRORA), OCT B-scans at the location of the future cRORA (case region) were evaluated for the presence of large drusen, drusenoid pigment epithelial detachments (PED), drusen with hyporeflective cores (hcD) subretinal drusenoid deposits (SDD), cuticular drusen, thick and thin double-layer signs (DLS), intraretinal hyperreflective foci (IHRF), and acquired vitelliform lesions (AVL). Regions within the same eye at the same distance from the fovea as the region which progressed to cRORA, but which did not progress to cRORA were selected as the control regions. The frequency of the OCT features in the case regions were compared to the control regions using chi-square test and associations were assessed by univariate and multivariate logistic regression analysis.

Results : A total of 57 AMD eyes (of 41 patients) with cRORA were included. Mean follow-up time was 44.69 ± 6.56 months. The presence of hcD, cuticular drusen, SDD, or thick DLS at baseline were not associated with an increased risk for development of cRORA at that location 4 years later (Table). Presence of large drusen, drusenoid PED, AVL, thin DLS, and IHRF were all associated with a significantly increased risk of cRORA at that location (Table). Multivariable logistic regression revealed that IHRF (P-value: <0.001, OR= 8.559), drusenoid PED (P-value: 0.001, OR= 7.148), and a thin DLS (P-value: 0.021, OR= 3.483) were independent predictors of development of cRORA at that location.

Conclusions : The presence of IHRF, drusenoid PED, and thin DLS are independent predictors of the development of cRORA at that same location. These findings would support the inclusion of these features within a more granular staging system defining specific steps in the progression from early dry AMD to atrophy.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×